SAN DIEGO, Aug. 24 /PRNewswire-FirstCall/ -- Orexigen((R)) Therapeutics, Inc. today announced that Mark Booth has joined the Company as Chief Commercial Officer. Mr. Booth brings over 25 years of commercial and business development experience to Orexigen. Most recently he served as President of Takeda Pharmaceuticals North America (TPNA) where he presided over the commercial, medical and scientific affairs, business development and all support functions. Under his leadership TPNA became one of the fastest growing pharmaceutical companies in the U.S. with sales of over $4 billion. Over the course of his career Mr. Booth has played an integral role in numerous co-development/co-promotional partnerships including Prevacid((R)), Enbrel((R)) and Actos((R)) which all achieved multi-billion dollar sales status.
Prior to his role at TPNA, Mr. Booth served as Senior Vice President, General Manager at Immunex Corporation where he was responsible for the sales, marketing and project management functions until the company was acquired by Amgen in 2002. Prior to his appointment at Immunex Corporation Mr. Booth was at Abbott Laboratories where he served in a range of leadership positions. In his last role he held the title of Division Vice President, General Manager for the $1 billion anti-infective franchise.
About Orexigen((R)) Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead investigational product, Contrave((R)), has completed Phase 3 clinical trials and is on track for a regulatory submission with the FDA in the first half of 2010. The Company's second product candidate, Empatic(TM), is in the later stages of Phase 2 clinical development, with results expected in the second half of 2009. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss, through combination therapeutic approaches. Further information about the Company can be found at http://www.Orexigen.com.
SOURCE Orexigen Therapeutics, Inc.
CONTACT: Graham Cooper of Orexigen, +1-858-875-8600; or Media, Liz Frank
for Orexigen, +1-212-301-7216
Web site: http://www.Orexigen.com/
